Kezar Life Sciences, Inc. (NASDAQ:KZR) Receives Consensus Rating of “Reduce” from Analysts

Shares of Kezar Life Sciences, Inc. (NASDAQ:KZR) have been given an average rating of “Reduce” by the six research firms that are currently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating and four have given a hold rating to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $6.00.

KZR has been the subject of several research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Kezar Life Sciences in a research report on Monday, December 22nd. Wall Street Zen upgraded Kezar Life Sciences to a “hold” rating in a report on Saturday, November 22nd.

Hedge Funds Weigh In On Kezar Life Sciences

Large investors have recently made changes to their positions in the business. Woodline Partners LP acquired a new stake in shares of Kezar Life Sciences during the first quarter worth approximately $125,000. BML Capital Management LLC grew its holdings in shares of Kezar Life Sciences by 55.6% during the 2nd quarter. BML Capital Management LLC now owns 635,183 shares of the company’s stock valued at $2,909,000 after acquiring an additional 227,045 shares in the last quarter. Stonepine Capital Management LLC increased its stake in shares of Kezar Life Sciences by 69.9% in the second quarter. Stonepine Capital Management LLC now owns 169,859 shares of the company’s stock worth $778,000 after acquiring an additional 69,859 shares during the last quarter. Peapod Lane Capital LLC increased its stake in shares of Kezar Life Sciences by 9.3% in the third quarter. Peapod Lane Capital LLC now owns 125,773 shares of the company’s stock worth $491,000 after acquiring an additional 10,650 shares during the last quarter. Finally, Landscape Capital Management L.L.C. purchased a new stake in shares of Kezar Life Sciences during the third quarter worth $51,000. Institutional investors and hedge funds own 67.90% of the company’s stock.

Kezar Life Sciences Price Performance

NASDAQ KZR opened at $6.53 on Thursday. The company has a current ratio of 7.07, a quick ratio of 7.06 and a debt-to-equity ratio of 0.02. Kezar Life Sciences has a 1 year low of $3.53 and a 1 year high of $6.66. The company has a market cap of $47.80 million, a PE ratio of -0.77 and a beta of 0.56. The stock’s 50-day moving average price is $6.24 and its two-hundred day moving average price is $5.37.

About Kezar Life Sciences

Kezar Life Sciences is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapies that modulate the innate immune system. The company’s research centers on selective inhibition of the immunoproteasome, a key protein complex involved in antigen processing and secretion of inflammatory cytokines. By targeting this pathway, Kezar aims to address unmet medical needs in autoimmune and inflammatory diseases with high specificity and a favorable safety profile.

The company’s lead development candidate, KZR-616, is a selective immunoproteasome inhibitor being evaluated in multiple clinical trials for autoimmune conditions such as systemic lupus erythematosus, lupus nephritis, polymyositis and dermatomyositis.